HLB Pharmaceutical Co

HLB Pharmaceutical Co EBIT

The EBIT of HLB Pharmaceutical Co (047920.KQ) as of Nov 3, 2026 is 5.07 B KRW. In the previous year, EBIT was 1.36 B KRW — a change of 273.58% (higher).

EBIT

5.07 BKRW

YoY

273.58%

Last updated:

In 2025, HLB Pharmaceutical Co's EBIT was 5.07 B KRW, a 273.58% increase from the 1.36 B KRW EBIT recorded in the previous year.

The HLB Pharmaceutical Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2017
-4.37 B KRW
Jan 1, 2018
-5.41 B KRW
Jan 1, 2019
1.00 B KRW
Jan 1, 2021
486.24 M KRW
Jan 1, 2022
-6.42 B KRW
Jan 1, 2023
-5.44 B KRW
Jan 1, 2024
1.36 B KRW
Jan 1, 2025
5.07 B KRW
The HLB Pharmaceutical Co EBIT history
YEAREBITYoY
5.07 BKRW+273.58%
1.36 BKRW-124.92%
-5.44 BKRW-15.15%
-6.42 BKRW-1,419.69%
486.24 MKRW-51.48%
1.00 BKRW-118.52%
-5.41 BKRW+23.95%
-4.37 BKRW-1,176.42%
405.55 MKRW-142.00%
-965.65 MKRW-322.78%
433.45 MKRW+38.92%
312.00 MKRW-72.96%
1.15 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HLB Pharmaceutical Co Revenue

HLB Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
20.54 B KRW
-5.41 B KRW
-7.06 B KRW
Jan 1, 2019
36.10 B KRW
1.00 B KRW
472.65 M KRW
Jan 1, 2020
40.57 B KRW
0.00 KRW
-74.84 B KRW
Jan 1, 2021
62.85 B KRW
486.24 M KRW
-13.23 B KRW
Jan 1, 2022
107.48 B KRW
-6.42 B KRW
-11.78 B KRW
Jan 1, 2023
135.95 B KRW
-5.44 B KRW
-19.43 B KRW
Jan 1, 2024
137.08 B KRW
1.36 B KRW
2.02 B KRW
Jan 1, 2025
205.58 B KRW
5.07 B KRW
4.57 B KRW

HLB Pharmaceutical Co Margins

HLB Pharmaceutical Co stock margins

The HLB Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of HLB Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for HLB Pharmaceutical Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
21.74 %
-26.34 %
-34.37 %
Jan 1, 2019
49.98 %
2.78 %
1.31 %
Jan 1, 2020
55.09 %
0.00 %
-184.47 %
Jan 1, 2021
56.25 %
0.77 %
-21.04 %
Jan 1, 2022
59.55 %
-5.97 %
-10.96 %
Jan 1, 2023
61.04 %
-4.01 %
-14.29 %
Jan 1, 2024
63.16 %
0.99 %
1.47 %
Jan 1, 2025
51.81 %
2.47 %
2.22 %

HLB Pharmaceutical Co Stock analysis

What does HLB Pharmaceutical Co do? HLB Pharmaceutical Co., Ltd. generates revenue through the manufacturing and sale of biotechnology-based pharmaceutical products. The company produces and sells cimetidine tablets, rozatin tablets, rabeprazole tablets, rozatinplus tablets, mosapia tablets, and other ethical the counter (ETC) drugs, as well as gynobetadine vaginal suppositories and other over the counter (OTC) drugs. Additionally, HLB offers commissioned ETC drugs such as aceclofenac tablets and revotec tablets, and commissioned OTC drugs including L-carnitine tablets, elcatan tablets, and hepatine liquids. These products are sold to healthcare providers, pharmacies, and consumers through established distribution channels. The primary customer segments for HLB's products include healthcare institutions requiring ETC drugs for prescription use, retail pharmacies selling OTC medications, and individual consumers purchasing OTC products directly. The company's product portfolio targets both prescription and non-prescription markets, with ETC drugs typically distributed through medical channels and OTC drugs available through general retail outlets. HLB's focus on biotechnology-driven formulations positions it within the pharmaceutical sector serving diverse healthcare needs. HLB's revenue streams are derived from direct sales of its branded pharmaceutical products to healthcare providers and retail networks. The company's ETC drugs, such as cimetidine and rabeprazole tablets, are primarily sold to hospitals and clinics for prescription use, while OTC products like gynobetadine vaginal suppositories and L-carnitine tablets reach consumers through pharmacy chains and online platforms. Commissioned products further diversify revenue by leveraging partnerships for manufacturing and distribution without direct brand ownership. HLB Pharmaceutical Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing HLB Pharmaceutical Co's EBIT

HLB Pharmaceutical Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of HLB Pharmaceutical Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

HLB Pharmaceutical Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in HLB Pharmaceutical Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about HLB Pharmaceutical Co stock

EBIT of HLB Pharmaceutical Co is 5.07 B KRW in 2025.

EBIT of HLB Pharmaceutical Co changed from 1.36 B KRW to 5.07 B KRW, representing a 273.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT HLB Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's HLB Pharmaceutical Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — HLB Pharmaceutical Co

All Key Metrics — HLB Pharmaceutical Co